The most powerful
genomic biomarker discovery platform

GEMMAai™

GEnoMic Marker Analyzer

AI-Powered platform for matching patients with right treatment

Most clinical trials fail

Most cancer treatments have low efficacy

GEMMAai™ PLATFORM

Utilizes 100% of tumor genome (SNV, CNV, genomic scars, structural rearrangements and more), professional expertise in big data analysis and AI approach combined with clinical information to dramatically improve patient stratification for cancer therapies.

How do we do it?

Our platform was created to base medical decisions on tumor genome profile (100% of genome analysed) rather than on standard treatment guidelines. Its key strengths lie in whole-genome sequencing, clinical data implementation, proprietary data mining, the AI, and the expertise.

Our proprietary software
for data mining

5410
whole-genome tumor data
153
genomic patterns (features)
9
AI-powered assays

Our pipeline

Our AI-powered methodology can be used to build a predictive model for any drug-response diagnostic tool, including PARP, CDK4/6 and mTOR inhibitors. The best results are obtained when both tumor whole genome data and clinical informations are available. However our extensive tumor genome database allows for diagnostics development for drugs where no clinical data is available (mechanism of action for a drug is sufficient).

GEMMAai for clinical trial enrolment – available
GEMMAai for companion diagnostics development – available
GEMMAai for patients coming soon – pipeline *

TUMOR
TYPE

TUMOR GENOMES

TARGETED THERAPY

DISCOVERY

PROTOTYPE ASSAY

ANALITYCAL VALIDATION

CLINICAL VALIDATION

REGULATORY APPROVAL

UPCOMING
MILESTONES

BREAST

2152

CDK4/6i
Ant-HER2
PARPi
mTORi
PIK3i

Title

65%

Title

65%

Title

40%

Title

15%

Title

15%

2 analytically validated diagnostic tools in Q1 2021

OVARIAN

512

Carboplatin / PARPi

Title

65%

FDA breakthrough device submission Q2 2021

FASETM

GENOMIC FEATURE DATABASE

YOUR inhibitor

Discovery and validation

AI-POWERED
STRATIFICATION DIAGNOSTIC TOOL

* For Research Use Only. Not for use in diagnostic procedures.

TUMOR TYPE: OVARIAN

WGS DATA

512

TARGETTED THERAPY

Carboplatin / PARPi

65%

UPCOMING MILESTONES

FDA breakthrough device in Q3 2021

TUMOR TYPE: BREAST

WGS DATA

2152

TARGETTED THERAPY

PARPi

40%

CDK4/6i

20%

Ant-HER2

40%

mTORi

15%

PIK3i

15%

UPCOMING MILESTONES

2 analytically validated diagnostic tools in Q1 2021

TUMOR TYPE: LUNG

WGS DATA

1852

TARGETTED THERAPY

PARPi

10%

immunotherapy

10%

UPCOMING MILESTONES

2 prototype assays in Q3 2021

FUSETM

WGS DATA

GENOMIC FEATURE DATABASE

TARGETTED THERAPY

YOUR inhibitor

DISCOVERY AND VALIDATION

AI-POWERED STRATIFICATION DIAGNOSTIC TOOL

Individual "Decision Tree" Construction

Random Forest Artificial Intelligence methodology based on Training Dataset

INSTEAD OF >1 000 SAMPLES, GEMMAaiTM

requires only 100 training datasets for a reliable output and achieves the optimal balance of sensitivity (recall) and precision.

Discrimination threshold

Learning curves

CARBOPLATIN/PARPi CLASSIFIER

_ALICE

ArtificiaL Intelligence ClassifiEr

NEW GLOBAL STANDARD IN OVARIAN ONCOLOGY THROUGH CONNECTING AI TECHNOLOGY TO WHOLE-GENOME DATA

Our proprietary software
for data mining

_ALICE is a Random Forest model, consisting of 100 decision trees. It analyses 44 genomic features associated with ovarian cancer treatment response. Apart from ‘gold standard’ biomarkers for HRD like BRCA1/2 mutations, deletions with microhomologies and tandem duplications, we have identified 3 novel biomarkers correlated with HRD and 22 important genomic biomarkers associated with PARPi clinical response.

Biomarker imporance

3
novel biomarkers correlated with HRD
22
novel important genomic biomarkers associated with PARPi clinical response
19
‘gold standard’ biomarkers

TECHNICAL NOTE

Read our tech note to learn how we constructed the _ALICE classificatory – from whole-genome data mining, feature extraction and engineering, through AI model development and retrospective validation.

Download



    I'm a patientI'm a doctorI'm a student
    I have read and agree to privacy policy and terms of service
    privacy policy
    terms of service

    Any questions?

    Contact us

      I have read and agree to privacy policy and terms of service
      privacy policy | terms of service

      In a hurry?

      Download a leaflet



        I'm a patientI'm a doctorI'm a student
        I have read and agree to privacy policy and terms of service
        privacy policy
        terms of servic